Sentynl Therapeutics

Focus: Sentynl Therapeutics is a small-molecule biotech company focused on neurology, oncology, and rare diseases, with a public listing and commercial-stage portfolio of four approved drugs.

Neurology Oncology Rare Diseases Unknown

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Sentynl Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Sentynl Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

3 in 5yr

NULIBRY

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

NULIBRY

Molybdenum cofactor deficiency Type A

Peak2.9yr

Rare disease orphan drug with substrate replacement mechanism addressing neurotoxic sulfite accumulation; LOE cliff in 4.5 years.

Help build intelligence for Sentynl Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Portfolio includes four FDA-approved products across high-need therapeutic areas (rare diseases, oncology, breakthrough pain), providing revenue stability — ZOKINVY and NULIBRY both at peak lifecycle with LOE protection through 2029
Rare disease focus (molybdenum cofactor deficiency, Menkes disease) offers specialized expertise and mission-driven work with limited competitive pressure
Public company status enables equity upside and transparent financial visibility, reducing startup-stage risk

Watch Out For

Minimal active pipeline: only 2 programs in development with no Phase 1/2/3 trials registered, suggesting limited future growth drivers beyond current marketed products
Approaching patent cliffs on two lead products (NULIBRY in 2029, ZOKINVY in 2029) create revenue cliff risk within 5 years with no obvious replacement pipeline
Only 3 active job openings and no disclosed employee count or hiring department breakdown signal limited headcount growth and potential career mobility constraints

Generated by Claude from Sentynl Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ZOKINVY

Farnesyltransferase inhibition (rare disease)

Peak3.2yr

Farnesyltransferase inhibitor at peak sales with patent protection until mid-2029; faces same LOE timeline as NULIBRY.

ABSTRAL

Breakthrough pain in cancer patients

LOE Approaching

Opioid agonist facing imminent loss of exclusivity with no disclosed LOE date; mature market with generic competition risk.

ZYCUBO

Menkes Disease

Launch4.7yr

Recently launched copper replacement therapy for rare genetic disorder; longest patent runway (6+ years) among portfolio.